<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570098</url>
  </required_header>
  <id_info>
    <org_study_id>EA1/178/19</org_study_id>
    <nct_id>NCT04570098</nct_id>
  </id_info>
  <brief_title>Prevalence and Prognostic Relevance of Tricuspid Regurgitation in Different Heart Failure Entities</brief_title>
  <official_title>Prevalence and Prognostic Relevance of Tricuspid Regurgitation in Different Heart Failure Entities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study includes patients with tricuspid regurgitation and heart failure diagnosed&#xD;
      with echocardiography. The aim is to evaluate the physical performance of patients with&#xD;
      tricuspid regurgitation and heart failure, to observe the course of the diseases and to allow&#xD;
      a better understanding of new therapy options.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Moderate to severe tricuspid regurgitation (TR) is a frequent result of left heart failure&#xD;
      causing a limiting prognosis. The new interventional therapies have given more relevance to&#xD;
      the questions of the prognostic significance of severe TR in the various heart failure&#xD;
      entities.&#xD;
&#xD;
      Important but currently unanswered questions for the establishment of successful,&#xD;
      interventional therapies of TR are:&#xD;
&#xD;
        1. What effect does TR have on patients with heart failure?&#xD;
&#xD;
        2. Which patients at which stage of the disease benefit from interventional TR-therapies?&#xD;
           In order to answer these questions, the aim of the study is to prospectively record the&#xD;
           prevalence of TR (including quantification) in all heart failure patients at the&#xD;
           Charité, followed by long-term observation to assess its prognostic relevance.&#xD;
&#xD;
      In addition to answering the above-mentioned questions, the project will allow a central&#xD;
      registration of all symptomatic heart failure patients. A comparative outcome analysis per&#xD;
      propensity score matching with the untreated patients of the registry would allow to give&#xD;
      first considerations which patients are ideal candidates for interventional therapies.&#xD;
&#xD;
      Primary endpoint: death Secondary endpoint: hospitalization due to cardiac decompensation,&#xD;
      exercise capacity according to NYHA classification&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>3 months after enrolment</time_frame>
    <description>Overall mortality after 3 months (number of deceased patients)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>24 months after enrolment</time_frame>
    <description>Overall mortality after 24 months (number of deceased patients)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hospitalization due to cardiac decompensation</measure>
    <time_frame>3 months after enrolment</time_frame>
    <description>number of hospitalized patients after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exercise capacity according to NYHA classification</measure>
    <time_frame>3 months after enrolment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization due to cardiac decompensation</measure>
    <time_frame>24 months after enrolment</time_frame>
    <description>number of hospitalized patients after 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exercise capacity according to NYHA classification</measure>
    <time_frame>24 months after enrolment</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <condition>Heart Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population include patients with heart failure (all three entities). All patients&#xD;
        will be examined with an echocardiography at the Charité, followed by long-term observation&#xD;
        to assess the prognostic relevance of tricuspid regurgitation in heart failure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with transthoracic echocardiography (TTE) and heart failure&#xD;
&#xD;
          -  Reported heart failure symptoms within the last two years&#xD;
&#xD;
          -  &gt;18 years&#xD;
&#xD;
          -  Written, documented consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patients in care or unable to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henryk Dreger, Prof. Dr. med.</last_name>
      <phone>+49 (0) 30 450 61 34 96</phone>
      <email>henryk.dreger@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Henryk Dreger</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>As part of the expected publications, it is planned to provide data of the study participants and more detailed information on inclusion and exclusion criteria (study protocol).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

